Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Digestive Advantage is a leading consumer health brand specializing in probiotic supplements designed to support digestive and immune health. The brand is centered around the patented probiotic strain BC30 (Bacillus coagulans GBI-30, 6086), which is distinguished by a natural protein shell that allows it to survive harsh stomach acid more effectively than many other strains. Originally developed by Ganeden Biotech, the brand was acquired by Schiff Nutrition in 2011 and later became part of the Reckitt portfolio following their acquisition of Schiff in 2012. Its product line includes a variety of formulations such as daily probiotics, intensive bowel support, and gas defense, available in formats like capsules and gummies. The brand targets common gastrointestinal issues including bloating, abdominal discomfort, and symptoms associated with Irritable Bowel Syndrome (IBS).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Digestive Advantage.